Table 3.
Recommended treatment based on chromosomal analysis
| Temo Followed by RT (%) | Concurrent Temo/RT Followed by Temo (%) | RT Followed by Temo (%) | Temo Alone (%) | RT Alone (%) | PCV and Then RT (%) | RT and Then PCV (%) | PCV Alone (%) | Other (%) | |
|---|---|---|---|---|---|---|---|---|---|
| 1p/19q unavailable | 12 | 32 | 22 | 11 | 7 | 9 | 4 | 0 | 4 |
| 1p/19q intact | 5 | 34 | 19 | 7 | 20 | 5 | 7 | 0 | 3 |
| 1p and 19q LOH | 11 | 18 | 11 | 34 | 4 | 7 | 5 | 8 | 3 |
| 1p LOH, 19q intact | 17 | 23 | 12 | 23 | 7 | 7 | 4 | 4 | 4 |
| 1p intact, 19q LOH | 11 | 31 | 14 | 14 | 11 | 8 | 5 | 3 | 4 |
Abbreviations: RT, radiotherapy; Temo, temozolomide; PCV, procarbazine, lomustine (CCNU), and vincristine; LOH, loss of heterozygosity.